Join Growin Stock Community!

Immix biopharma, inc.IMMX.US Overview

US StockHealthcare
(No presentation for IMMX)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

IMMX AI Insights

IMMX Overall Performance

IMMX AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

IMMX Recent Performance

3.53%

Immix biopharma, inc.

0.05%

Avg of Sector

-0.31%

S&P500

IMMX PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

IMMX Key Information

IMMX Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

IMMX Profile

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.

Price of IMMX

IMMX FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

IMMX Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.70
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
51.64
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.70
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
51.64
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is IMMX's latest earnings report released?

    The most recent financial report for Immix biopharma, inc. (IMMX) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating IMMX's short-term business performance and financial health. For the latest updates on IMMX's earnings releases, visit this page regularly.

  • How much debt does IMMX have?

    As of the end of the reporting period, Immix biopharma, inc. (IMMX) had total debt of 1.11M, with a debt ratio of 0.06. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does IMMX have?

    At the end of the period, Immix biopharma, inc. (IMMX) held Total Cash and Cash Equivalents of 15.95M, accounting for 0.79 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • What is the FCF of IMMX?

    Immix biopharma, inc. (IMMX)'s Free Cash Flow (FCF) for the period is -6.28M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 45.75% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of IMMX?

    The latest valuation data shows Immix biopharma, inc. (IMMX) has a Price-To-Earnings (PE) ratio of -4.49 and a Price/Earnings-To-Growth (PEG) ratio of -0.24. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.